MedTrace Logo

Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis

NCT00525902 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2012-04-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety and efficacy of Adalimumab in uveitis.

Conditions

  • Uveitis

Interventions

DRUG

Adalimumab

40 mg delivered every 2 weeks by subcutaneous injection

Sponsors & Collaborators

  • University of Illinois at Chicago

    collaborator OTHER

  • The Cleveland Clinic

    collaborator OTHER

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • Eric B Suhler, MD · Oregon Health and Science University

  • James T Rosenbaum, MD · Oregon Health and Science University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00525902 on ClinicalTrials.gov